Trial Results Show Impressive Benefit of Carfilzomib (Kyprolis®) versus Bortezomib (Velcade®) in Relapsed Myeloma

This week’s news of interim results from the ENDEAVOR trial, a head-to-head comparison of “real world” schedules of Kyprolis versus Velcade, reveals an impressive benefit of carfilzomib over bortezomib in relapsed myeloma. Indeed, the 929-patient phase III trial showed a progression-free survival (PFS) of 18.7 months for Kyprolis versus 9.4 months for Velcade—basically a doubling of PFS or remission duration.

FDA Reverses ODAC Vote and Approves Panobinostat (Farydak®) for Relapsed Myeloma

In a surprise move this week, the US Food and Drug Administration (FDA) approved Farydak®, despite the 5-2 vote by the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommending against approval in November 2014. The approval is obviously good news for the myeloma community.